| Literature DB >> 30976014 |
Thao Van Nguyen1, Andrea C Alfaro2, Tim Young1, Saras Green3, Erica Zarate3, Fabrice Merien4.
Abstract
The antimicrobial role of itaconic acid (ITA) has been recently discovered in mammalian cells. In our previous studies, we discovered that marine molluscs biosynthesise substantial quantities of ITA when exposed to marine pathogens, but its antimicrobial function to Vibrio bacteria is currently unknown. Thus, in this study, we used an untargeted gas chromatography-mass spectrometry (GC-MS) platform to identify metabolic changes of Vibrio sp. DO1 (V. corallyliticus/neptunius-like isolate) caused by ITA exposure. Vibrio sp. DO1 was cultured in Luria-Bertani broth supplemented with 3 mM sodium acetate and with different concentrations of ITA (0, 3 and 6 mM) for 24 h. The results showed that ITA completely inhibited Vibrio sp. growth at 6 mM and partially inhibited the bacterial growth at 3 mM. A principal component analysis (PCA) revealed a clear separation between metabolite profiles of Vibrio sp. DO1 in the 3 mM ITA treatment and the control, which were different in 25 metabolites. Among the altered metabolites, the accumulation of glyoxylic acid and other metabolites in glyoxylate cycle (cis-aconitic acid, isocitric acid and fumaric acid) together with the increase of isocitrate lyase (ICL) activity in the 3 mM ITA treatment compared to the control suggest that ITA inhibited Vibrio sp. growth via disruption of central carbon metabolism.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30976014 PMCID: PMC6459830 DOI: 10.1038/s41598-019-42315-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Effects of ITA on growth of Vibrio sp. and isocitrate and isocitrate lyase (ICL). (a) The absorbance (600 nm) of Vibrio sp. cultured in different ITA concentrations (0, 3 and 6 mM) supplemented with sodium acetate over 24 h. (b) Level of isocitrate in the 3 mM ITA treatment and the control at 24 hpi. (c) Activity of ICL in the 3 mM ITA treatment and the control at 24 hpi. Data are presented as mean ± S.D. (n = 6). Significant differences relative to the control are marked with an asterisk (*) (t-test, p < 0.05).
Figure 2Effects of ITA on metabolite profiles of Vibrio sp. in the 3 mM ITA treatment and the control. (a) Classification of the metabolites. (b) PLS-DA score plot. (c) Heatmap of 25 metabolites identified as significantly different between the ITA treatment and the control by t-test (p < 0.05). CON, control treatment (no ITA); ITA, 3 mM ITA treatment.
Figure 3Effects of ITA on glyoxylate shunt of Vibrio sp. cultured in LB media with and without ITA. (a) Altered metabolites of glyoxylate shunt identified by t-test (p < 0.05). Box plots show relative abundances of metabolites after normalization (b) Univariate ROC curve analysis of significantly altered metabolites (ITA/Non ITA) of the glyoxylate shunt. (c) Multivariate ROC curve-based model evaluation of all altered metabolites in the glyoxylate shunt identified by ROC curve analysis.
List of metabolic pathways in Vibrio sp. that were significantly affected by ITA exposure.
| Pathways | Hits/Total compounds | Raw p | FDR | Impact |
|---|---|---|---|---|
| Alanine, aspartate and glutamate metabolism | 6/18 | <0.001 | <0.001 | 0.479 |
| Glycine, serine and threonine metabolism | 6/32 | 0.001 | 0.001 | 0.473 |
| Pyruvate metabolism | 3/26 | 0.005 | 0.007 | 0.438 |
| Glutathione metabolism | 5/21 | <0.001 | <0.001 | 0.381 |
| Citrate cycle (TCA cycle) | 8/20 | <0.001 | <0.001 | 0.301 |
| Butanoate metabolism | 4/18 | <0.001 | 0.001 | 0.255 |
| Cysteine and methionine metabolism | 6/34 | 0.001 | 0.001 | 0.230 |
| Arginine and proline metabolism | 8/41 | <0.001 | 0.001 | 0.215 |
| Glycolysis or Gluconeogenesis | 2/29 | 0.192 | 0.192 | 0.168 |
| Methane metabolism | 2/11 | <0.001 | <0.001 | 0.167 |
| Aminoacyl-tRNA biosynthesis | 18/66 | <0.001 | <0.001 | 0.130 |
| Glyoxylate and dicarboxylate metabolism | 5/29 | <0.001 | <0.001 | 0.102 |
| Nicotinate and nicotinamide metabolism | 2/13 | 0.001 | 0.001 | 0.089 |
| Sulfur metabolism | 2/13 | 0.001 | 0.001 | 0.069 |
| Valine, leucine and isoleucine biosynthesis | 5/26 | <0.001 | <0.001 | 0.036 |
| C5-Branched dibasic acid metabolism | 2/6 | <0.001 | <0.001 | 0.000 |
| Benzoate degradation via CoA ligation | 3/10 | <0.001 | <0.001 | 0.000 |
| Valine, leucine and isoleucine degradation | 3/23 | <0.001 | <0.001 | 0.000 |
| beta-Alanine metabolism | 2/16 | <0.001 | 0.001 | 0.000 |
| Nitrogen metabolism | 5/18 | <0.001 | 0.001 | 0.000 |
| Phenylalanine, tyrosine and tryptophan biosynthesis | 4/23 | <0.001 | 0.001 | 0.000 |
| Thiamine metabolism | 2/19 | <0.001 | 0.001 | 0.000 |
| Lysine biosynthesis | 2/13 | <0.001 | 0.001 | 0.000 |
| Cyanoamino acid metabolism | 4/8 | 0.001 | 0.001 | 0.000 |
| Phenylalanine metabolism | 4/23 | 0.001 | 0.001 | 0.000 |
| Pantothenate and CoA biosynthesis | 4/23 | 0.001 | 0.001 | 0.000 |
| Tyrosine metabolism | 2/10 | 0.002 | 0.003 | 0.000 |
| Biosynthesis of unsaturated fatty acids | 3/6 | 0.011 | 0.015 | 0.000 |
Figure 4The general scheme for tricarboxylic acid (TCA) cycle (black arrows) and glyoxylate cycle (blue arrows). Box plots show relative abundances of metabolites after normalization and significant differences relative to the control are marked with an asterisk (*) (t-test, p < 0.05).